Lanifibranor is a new, pan-PPAR agonist, which showed improvements in liver fibrosis and markers of cardiometabolic health in a phase IIb trial in patients with MASH [87, 88]. The gene discussed is PPARA; the disease is metabolic dysfunction-associated steatohepatitis.